Patents by Inventor Mark Alan Winter

Mark Alan Winter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Excitatory amino acid receptor antagonists
    Publication number: 20040138254
    Abstract: The present invention provides novel compounds of Formula (I) and Formula (I(a)), or the pharmaceutically acceptable salts thereof; methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine, comprising administering a compound of Formula (I) or Formula (I(a)); and processes for preparing compounds of Formula (I) or Formula (I(a)).
    Type: Application
    Filed: December 1, 2003
    Publication date: July 15, 2004
    Inventors: Macklin Brian Arnold, Thomas John Bleisch, Ana Maria Castano Mansanet, Esteban Dominguez-Manzanares, Jose Antonio Martinez-Perez, Ana Maria Escribano, Ana Isabel Mateo Herranz, Paul Leslie Ornstein, Mark Alan Winter, Scott Allan May, Andrew Michael Ratz, Thomas Michael Wilson
  • Selective iglur5 receptor antagonists
    Patent number: 6579886
    Abstract: The present invention provides compounds of formula (I): wherein W represents hydrogen, C1-C4 alkyl, —CH2CO2H, or CO2H; and X represents hydrogen, C1-C4 alkyl, —CH2CO2H, or CO2H; with the proviso that at least one of W or X must be other than hydrogen; or a prodrug or a pharmaceutically acceptable salt thereof; which are useful for treating migraine.
    Type: Grant
    Filed: September 3, 2002
    Date of Patent: June 17, 2003
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Michael Edward Le Tourneau, Michael John Martinelli, Mark Alan Winter
  • Selective iglur5 receptor antagonists
    Publication number: 20030055081
    Abstract: The present invention provides compounds of formula (I): wherein W represents hydrogen, C1-C4 alkyl, —CH2CO2H, or CO2H; and X represents hydrogen, C1-C4 alkyl, —CH2CO2H, or CO2H; with the proviso that at least one of W or X must be other than hydrogen; or a prodrug or a pharmaceutically acceptable salt thereof; which are useful for treating migraine.
    Type: Application
    Filed: September 3, 2002
    Publication date: March 20, 2003
    Inventors: Michael Gregory Bell, Michael Edward LeTourneau, Michael John Martinelli, Mark Alan Winter
  • Selective &bgr;3 adrenergic agonists
    Patent number: 6265581
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective &bgr;3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.
    Type: Grant
    Filed: April 17, 2000
    Date of Patent: July 24, 2001
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, Christine Ann Droste, Cynthia Darshini Jesudason, Donald Paul Matthews, John Hampton McDonald, III, David Andrew Neel, Christopher John Rito, Anthony John Shuker, Mark Alan Winter
  • Benzo[B]indeno[2, 1-D]thiophene compounds, intermediates, compositions, and methods
    Patent number: 6133458
    Abstract: The invention provides benzo[b]indenothiophene compounds, intermediates, formulations, and methods of inhibiting bone loss or bone resorption, particularly osteoporosis, cardiovascular-related pathological conditions including hyperlipidemia and related cardiovascular pathologies, and estrogen-dependent cancer.
    Type: Grant
    Filed: September 30, 1998
    Date of Patent: October 17, 2000
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Brian Stephen Muehl, Mark Alan Winter
  • Selective .beta.-3 adrenergic agonists
    Patent number: 6093735
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.
    Type: Grant
    Filed: July 1, 1999
    Date of Patent: July 25, 2000
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, Christine Ann Droste, Cynthia Darshini Jesudason, Donald Paul Matthews, John Hampton McDonald, III, David Andrew Neel, Christopher John Rito, Anthony John Shuker, Mark Alan Winter
  • Selective .beta..sub.3 adrenergic agonists
    Patent number: 6075040
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.
    Type: Grant
    Filed: May 2, 1997
    Date of Patent: June 13, 2000
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, Cynthia Darshini Jesudason, Donald Paul Matthews, John Hampton McDonald, III, David Andrew Neel, Christopher John Rito, Anthony John Shuker, Mark Alan Winter
  • Selective .beta.3 adrenergic agonists
    Patent number: 6060492
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formula II: ##STR1## The variables in Formula II are defined herein.
    Type: Grant
    Filed: June 25, 1997
    Date of Patent: May 9, 2000
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, Donald Paul Matthews, John Hampton McDonald, III, David Andrew Neel, Anthony John Shuker, Mark Alan Winter
  • Selective .beta.3 adrenergic agonist
    Patent number: 5977154
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.
    Type: Grant
    Filed: June 26, 1997
    Date of Patent: November 2, 1999
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Christine Ann Droste, Cynthia Darshini Jesudason, Christopher John Rito, Anthony John Shuker, Mark Alan Winter
  • Selective .beta.3 adrenergic agonists
    Patent number: 5939443
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formula II: ##STR1## The variables in Formula II are defined herein.
    Type: Grant
    Filed: June 25, 1997
    Date of Patent: August 17, 1999
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, Christine Ann Droste, Donald Paul Matthews, John Hampton McDonald, III, Christopher John Rito, Anthony John Shuker, Mark Alan Winter
  • Benzo ?B! indeno ?2,1-D! thiophene compounds, intermediates, processes, compositions and methods
    Patent number: 5856341
    Abstract: The invention provides benzo?b!indenothiophene compounds of formula I ##STR1## wherein, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.6, are as defined in the specification, intermediates, formulations, and methods of inhibiting bone loss or bone resorption, particularly osteoporosis, cardiovascular-related pathological conditions including hyperlipidemia and related cardiovascular pathologies, and estrogen-dependent cancer.
    Type: Grant
    Filed: September 19, 1997
    Date of Patent: January 5, 1999
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Brian Stephen Muehl, Mark Alan Winter
  • Selective .beta.-3 adrenergic agonists
    Patent number: 5840738
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.
    Type: Grant
    Filed: June 25, 1997
    Date of Patent: November 24, 1998
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, Christine Ann Droste, Cynthia Darshini Jesudason, Donald Paul Matthews, John Hampton McDonald, III, David Andrew Neel, Christopher John Rito, Anthony John Shuker, Mark Alan Winter
  • Dihydrobenzo ?B! indeno ?2, 1-D! thiophene compounds, intermediates, processes, compositions and methods
    Patent number: 5834488
    Abstract: The invention provides dihydrobenzo?b!indenothiophene compounds, intermediates, processes, formulations, and methods of inhibiting bone loss or bone resorption, particularly osteoporosis, cardiovascular-related pathological conditions including hyperlipidemia and related cardiovascular pathologies, and estrogen-dependent cancer.
    Type: Grant
    Filed: September 19, 1997
    Date of Patent: November 10, 1998
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Brian Stephen Muehl, Mark Alan Winter
  • Selective .beta.3 adrenergic agonists
    Patent number: 5808080
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.
    Type: Grant
    Filed: May 2, 1997
    Date of Patent: September 15, 1998
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, David Andrew Neel, Mark Alan Winter
  • Selective .beta.3 adrenergic agonists
    Patent number: 5786356
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.
    Type: Grant
    Filed: June 25, 1997
    Date of Patent: July 28, 1998
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, Donald Paul Matthews, John Hampton McDonald, III, David Andrew Neel, Anthony John Shuker, Mark Alan Winter